SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FCEL is trending due to increased interest in fuel cell technology, particularly after competitor Bloom Energy announced a significant deal related to AI infrastructure. The community is discussing FCEL's potential role in powering data centers and whether it can replicate Bloom's success, with some drawing comparisons to $BE's market performance.

MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane, EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matrix derived from the placental disc and other placental tissue. The company was founded on July 30, 1985 and is headquartered in Marietta, GA.

Mimedx Group Inc

Mimedx Group Inc. is trending due to anticipation and discussion surrounding a final rule impacting reimbursement pricing for skin substitutes, with the community debating potential outcomes and a CMS price prediction. Community members express both optimism and concern regarding the impact of the ruling, specifically referencing political factors and comparing MDXG to competitors. Some investors speculate about potential M&A activity, encouraged by recent positive earnings and long-term growth.

Mannatech, Inc. engages in the development of nutritional supplements, topical and skin care products and weight-management products that target optimal health and wellness. Its product category includes integrative health, targeted health, wealth and fitness, skin care, essentials, and home. The company was founded by Marlin Ray Robbins and Samuel L. Caster in November 1993 and is headquartered in Flower Mound, TX.

Mannatech Inc

MTEX is trending due to a potential short squeeze driven by its small float and recent price and volume spikes. Community members are closely watching key breakout levels, anticipating a significant move, with some comparing it to recent low-float runners. The stock's potential for a multi-day run is fueling excitement as traders look for the next big opportunity.

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell on June 29, 2022 and is headquartered in New York, NY.

Metsera Inc.

Metsera Inc

MTSR is trending due to a potential bidding war between Novo Nordisk and Pfizer to acquire the company and its obesity drug pipeline, with Pfizer even filing a lawsuit related to the offers. Community members are discussing whether Pfizer will increase its bid or if another company like Eli Lilly could enter the competition. The surge in interest is also fueled by recent data, though some debate the drug's efficacy and side effect profile compared to competitors.

Tidal Trust II - YieldMax Dorsey Wright Featured 5 Income ETF

YieldMax Dorsey Wright Featured 5 Income ETF

Investors are closely watching $FEAT, a YieldMax ETF, as it transitions to weekly distributions, sparking discussions around payout estimates and the impact on cash flow. The community is also focused on the ETF's top holdings and its actively managed options strategies, particularly after YieldMax announced changes to their distribution schedule. Some are expressing concerns about the ETF's performance since inception, while others remain optimistic about its high yield potential.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Emergent BioSolutions is trending due to a potential short squeeze, fueled by a significant increase in short borrow fees and positive community sentiment. The community is actively discussing the possibility of a squeeze, referencing analyst upgrades and increased Q4 EPS estimates. Discussions also highlight the company's financials, potential debt restructuring, and speculation about a potential buyout.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk (NVO) is trending due to concerns about its competitive positioning against Eli Lilly ($LLY) and Pfizer ($PFE) in the obesity and diabetes market, particularly after a failed acquisition bid and new competition. The community is discussing the potential impact of a government shutdown on FDA approvals and the implications of leadership changes within the company. Some investors are expressing frustration with the stock's recent performance, while others see it as a long-term value opportunity.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilio is trending following positive Q3 results and an optimistic AI-driven outlook, leading to a 20% stock surge. The community is discussing the potential for further gains, with many analysts raising price targets. Some investors feel they sold their positions too early before the recent surge.

Newsmax Inc. is a holding company, which engages in television broadcasting and multi-platform content publishing that produces original news and editorial content for consumers through various media outlets, including TV new channels, digital and print publications. It operates through the Broadcasting and Digital Segments. The Broadcasting segment produces and licenses news, business news and lifestyle content for distribution through both MVPDs and free OTT streaming platforms. The Digital segment is composed of Newsmax.com and affiliated websites. The company was founded by Christopher Ruddy in 1998 and is headquartered in Boca Raton, FL.

Newsmax Inc. - Ordinary Shares - Class B

Newsmax Inc

Newsmax is trending as community members discuss the stock's potential connection to Trump Coin and the broader MAGA movement, with some pointing to large short positions held by major Trump donors. Concerns about market manipulation and the stock's valuation relative to its IPO price are also circulating among investors. Additionally, discussion of Newsmax's recent deal for channel availability in hotels nationwide is present.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassian ($TEAM) is trending amid positive sentiment following earnings and revenue beats, with cloud strength and AI integration driving momentum. The community is discussing raised guidance and a new $2.5B buyback program, while also debating the impact of insider selling and the stock's potential to reach analyst price targets. Overall, investors are weighing the company's growth prospects against broader market conditions and sector-specific challenges.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NewAmsterdam Pharma Company N.V. (NAMS) Expected to Beat Earnings Estimates: Should You Buy?

NewAmsterdam Pharma Company N.V. (NAMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 4, 2025. The company will also host a...

Analysts Estimate Corcept Therapeutics (CORT) to Report a Decline in Earnings: What to Look Out for

Corcept (CORT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

<p>Corcept Therapeutics shares&nbsp;fell 0.9% in premarket trading Monday&nbsp;despite the company reporting late-breaking Phase 3 data showing its drug relacorilant improved outcomes in patients with platinum-resistant ovarian cancer, including those who had previously taken PARP inhibitors.</p><h2 class="st-heading-2"><strong>Relacorilant Improves Survival In Difficult-To-Treat Patients</strong></h2><p>The new results came from the late-stage ROSELLA trial, which tested relacorilant alongside nab-paclitaxel chemotherapy. Patients who had already stopped responding to PARP inhibitor treatment saw a 40% lower risk of their cancer worsening or leading to death when given the combination compared with chemotherapy alone. Median progression-free survival was 7.36 months in both PARP-experienced subgroups, according to the company.</p><p>Relacorilant works by blocking cortisol’s effects, which can promote tumor growth and resistance to chemotherapy. The company said the therapy was well tolerated, with adverse events comparable to standard chemotherapy. Corcept noted that relacorilant achieved its benefit without adding to patients’ safety burden.</p><h2 class="st-heading-2"><strong>Broader Trial Expansion Underway</strong></h2><p>Corcept also announced an expansion of its Phase 2 BELLA trial to include three study arms, which include platinum-resistant ovarian cancer, platinum-sensitive ovarian cancer, and endometrial cancer. Early data from these studies are expected in late 2026.</p><p>Chief Development Officer Bill Guyer said the new results strengthen confidence in relacorilant’s potential, adding that the FDA’s recent acceptance of the company’s New Drug Application (NDA) for platinum-resistant ovarian cancer brings Corcept “closer than ever” to delivering a new treatment option.</p><h2 class="st-heading-2"><strong>Regulatory Path&nbsp;</strong></h2><p>The FDA has set a July 11, 2026, PDUFA date for relacorilant in platinum-resistant ovarian cancer and a Dec. 30 date for its hypercortisolism indication. The company has also filed for European approval.</p><h2 class="st-heading-2"><strong>Stocktwits Users Turn Bullish As Corcept Bounces Off Support</strong></h2><p>On Stocktwits, retail sentiment for Corcept Therapeutics was ‘bullish’ amid ‘high’ message volume.</p><p>One user said they saw the update as a sign of renewed investor optimism and planned to keep holding their shares.</p><p><stembedurl>https://stocktwits.com/TheAlmani/message/632887580</stembedurl></p><p>Another pointed to a technical rebound in the stock, saying they were averaging down after what they viewed as a bounce off support.</p><p><stembedurl>https://stocktwits.com/Silent_Raven6450/message/632899741</stembedurl></p><p><a href="https://stocktwits.com/symbol/CORT">Corcept’s stock</a> has risen 56% so far in 2025.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Corcept’s stock (CORT) has risen 56% so far in 2025. | Image source: Getty Images

 Corcept Therapeutics Stock Slips Premarket Despite Strong Cancer Trial Data Showing 40% Drop In Disease Progression Risk

Phase 3 ROSELLA trial showed relacorilant plus chemotherapy helped patients with platinum-resistant ovarian cancer live longer without disease worsening, including those who failed prior PARP inhibitor treatment.

Equity

The Phase 3 ROSELLA trial showed relacorilant plus chemotherapy helped patients with platinum-resistant ovarian cancer live longer without disease worsening, including those who failed prior PARP inhibitor treatment.

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and...

CORT Files MAA for Relacorilant in Platinum-Resistant Ovarian Cancer

Corcept files a marketing application with the EMA for relacorilant in platinum-resistant ovarian cancer after studies show survival gains.

Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer

Can Relacorilant Drive Corcept's Long-Term Growth Beyond Korlym?

Corcept expects relacorilant to ease sole reliance on Korlym for revenues. Relacorilant is under FDA review for Cushing's syndrome and ovarian cancer.

FDA Accepts Corcept's NDA for Relacorilant in Ovarian Cancer

CORT's NDA for relacorilant in platinum-resistant ovarian cancer gains FDA acceptance, with a decision expected by July 2026.

Can Korlym Drive Corcept's Growth Through the Rest of 2025?

CORT projects $850-$900M in 2025 revenues as Korlym sales rise and relacorilant nears an FDA decision for Cushing's syndrome.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Palantir Technologies Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

CORT
Corcept Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CORT News

CORTCorcept Therapeutics Inc